DSV drags down Kuehne as Schenker 'update' saves the day
A one-off excuse
TSLA: FEEL THE PAIN IN CHINAWMT: GUESS WHATXPO: SURGINGAMZN: LOOKING FORWARDCHRW: PAYOUT UNCHANGEDWTC: NEW HIGH MAERSK: 'AFLOAT IN A SEA OF RISK' F: TARIFF TRAFFIC WARNINGHON: GAUGE THE UPSIDEXPO: STELLAR EARNINGS DELIVERYMAERSK: DEMAND DISRUPTION RISKMAERSK: FOCUS ON MARGIN IN LOGISTICS AND SERVICESMAERSK: GROWTH UNDERPERFORMANCE IN OCEAN MAERSK: WHY IS GEMINI SUCH A GOOD IDEA MAERSK: INTEGRATOR STRATEGY MAERSK: EIGHT YEARS AFTER THE LAUNCH OF THE INTEGRATOR STRATEGYMAERSK: FOCUS ON DEALS MAERSK: QUESTION TIME WITH FOCUS ON MSC AND DEALS
TSLA: FEEL THE PAIN IN CHINAWMT: GUESS WHATXPO: SURGINGAMZN: LOOKING FORWARDCHRW: PAYOUT UNCHANGEDWTC: NEW HIGH MAERSK: 'AFLOAT IN A SEA OF RISK' F: TARIFF TRAFFIC WARNINGHON: GAUGE THE UPSIDEXPO: STELLAR EARNINGS DELIVERYMAERSK: DEMAND DISRUPTION RISKMAERSK: FOCUS ON MARGIN IN LOGISTICS AND SERVICESMAERSK: GROWTH UNDERPERFORMANCE IN OCEAN MAERSK: WHY IS GEMINI SUCH A GOOD IDEA MAERSK: INTEGRATOR STRATEGY MAERSK: EIGHT YEARS AFTER THE LAUNCH OF THE INTEGRATOR STRATEGYMAERSK: FOCUS ON DEALS MAERSK: QUESTION TIME WITH FOCUS ON MSC AND DEALS
Logistics professionals in the pharmaceutical sector need to push for “better alignment on handling and transport standards”.
At yesterday’s Temperature Controlled Logistics conference in London, Amelia Binci, director of external quality assurance for distribution and logistics at pharma manufacturer MSD, said alignment was her main challenge when selecting suppliers.
“Particularly in terms of standardised requirements,” she added.
“In the guidelines [Good Distribution Practice, 2013], there are generalisations that are there on purpose so the experts, those moving the goods, can set the appropriate measures.
“But these guidelines are based on minimum standards and for us this isn’t enough, we want the same standard globally.”
Head of pharma at Kuehne + Nagel David Cunniffe said when K+N selected transport providers it looked to certification from industry bodies to ensure standardised practices.
“For instance, it is about selecting airlines that can handle pharmaceuticals, so we look for those that have received IATA’s Centre of Excellence for Independent Validators (CEIV) certification,” said Mr Cunniffee.
“The shipments we are typically transporting by air are valued at anywhere between $3m and $10m, so we cannot afford any deviation in temperatures.”
Ms Binci said she was optimistic about raising standards in emerging markets, where many were looking to European operators and seeing their standards as those to follow. She believed this provided a platform for emerging markets to catch up while maintaining quality.
“Even so, I still have a lot of problems to be overcome, notably in ocean logistics, where I question the importance of the pharma business,” she said. “It strikes me that pharma manufacturers have a lack of leverage in this market, where perhaps the ocean carriers consider the shipments we provide to be of less importance. How important is pharmaceuticals for these transport companies?”
The director of pharma ocean freight specialist Team Poseidon, Alan Kennedy, told The Loadstar his firm’s plan for a less-than-containerload (LCL) service for SME shippers would open a “huge market” for pharmaceuticals to be shipped by sea.
“Some 40%-50% of pharmaceuticals are produced by small shippers and none goes by sea, because these companies are not manufacturing the volumes to make using a full container economically viable,” said Mr Kennedy.
“With an LCL service, the prospect of sending their goods by ocean becomes not only more viable, but makes much more sense.”
Comment on this article